Archetypal Analysis of Injury in Kidney Transplant Biopsies Identifies Two Classes of Early AKI.

archetypes biopsy gene expression injury kidney transplantation

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 17 11 2021
accepted: 07 03 2022
entrez: 25 4 2022
pubmed: 26 4 2022
medline: 26 4 2022
Statut: epublish

Résumé

All transplanted kidneys are subjected to some degree of injury as a result of the donation-implantation process and various post-transplant stresses such as rejection. Because transplants are frequently biopsied, they present an opportunity to explore the full spectrum of kidney response-to-wounding from all causes. Defining parenchymal damage in transplanted organs is important for clinical management because it determines function and survival. In this study, we classified the scenarios associated with parenchymal injury in genome-wide microarray results from 1,526 kidney transplant indication biopsies collected during the INTERCOMEX study. We defined injury groups by using archetypal analysis (AA) of scores for gene sets and classifiers previously identified in various injury states. Six groups and their characteristics were defined in this population: No injury, minor injury, two classes of acute kidney injury ("AKI," AKI1, and AKI2), chronic kidney disease (CKD), and CKD combined with AKI. We compared the two classes of AKI, namely, AKI1 and AKI2. AKI1 had a poor function and increased parenchymal dedifferentiation but minimal response-to-injury and inflammation, instead having increased expression of PARD3, a gene previously characterized as being related to epithelial polarity and adherens junctions. In contrast, AKI2 had a poor function and increased response-to-injury, significant inflammation, and increased macrophage activity. In random forest analysis, the most important predictors of function (estimated glomerular filtration rate) and graft loss were injury-based molecular scores, not rejection scores. AKI1 and AKI2 differed in 3-year graft survival, with better survival in the AKI2 group. Thus, injury archetype analysis of injury-induced gene expression shows new heterogeneity in kidney response-to-wounding, revealing AKI1, a class of early transplants with a poor function but minimal inflammation or response to injury, a deviant response characterized as PC3, and an increased risk of failure. Given the relationship between parenchymal injury and kidney survival, further characterization of the injury phenotypes in kidney transplants will be important for an improved understanding that could have implications for understanding native kidney diseases (ClinicalTrials.gov #NCT01299168).

Identifiants

pubmed: 35463013
doi: 10.3389/fmed.2022.817324
pmc: PMC9021747
doi:

Banques de données

ClinicalTrials.gov
['NCT01299168']

Types de publication

Journal Article

Langues

eng

Pagination

817324

Informations de copyright

Copyright © 2022 Halloran, Böhmig, Bromberg, Einecke, Eskandary, Gupta, Myslak, Viklicky, Perkowska-Ptasinska, Madill-Thomsen and the INTERCOMEX Investigators.

Déclaration de conflit d'intérêts

PH is a consultant to Natera, holds shares in Transcriptome Sciences Inc (TSI), a University of Alberta research company dedicated to developing molecular diagnostics, supported in part by a licensing agreement between TSI and Thermo Fisher, and by a research grant from Natera. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Transplant. 2021 Apr;21(4):1391-1401
pubmed: 32594646
Am J Transplant. 2017 Nov;17(11):2851-2862
pubmed: 28449409
Am J Transplant. 2019 Oct;19(10):2719-2731
pubmed: 30868758
BMC Bioinformatics. 2013 Sep 23;14:279
pubmed: 24059747
Am J Transplant. 2017 Jan;17(1):28-41
pubmed: 27862883
Am J Transplant. 2017 Aug;17(8):2117-2128
pubmed: 28226404
Am J Transplant. 2008 Jul;8(7):1434-43
pubmed: 18444922
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
JCI Insight. 2017 Jun 15;2(12):
pubmed: 28614805
Am J Transplant. 2019 May;19(5):1356-1370
pubmed: 30417539
Am J Transplant. 2020 Sep;20(9):2305-2317
pubmed: 32428337
JCI Insight. 2016 Jan 21;1(1):e85323
pubmed: 27699214
Am J Transplant. 2016 Dec;16(12):3338-3361
pubmed: 27421829
Front Plant Sci. 2014 Oct 31;5:578
pubmed: 25400647
Am J Transplant. 2021 May;21(5):1725-1739
pubmed: 33107191
Am J Transplant. 2007 Nov;7(11):2483-95
pubmed: 17908279
Nat Rev Nephrol. 2016 Sep;12(9):534-48
pubmed: 27345248
JCI Insight. 2016;1(7):
pubmed: 27280173
J Am Soc Nephrol. 2012 May;23(5):948-58
pubmed: 22343120
Am J Transplant. 2010 Oct;10(10):2241-51
pubmed: 20883558
Am J Transplant. 2009 Jan;9(1):169-78
pubmed: 18976290
PLoS Comput Biol. 2015 Jul 10;11(7):e1004224
pubmed: 26161936

Auteurs

Philip F Halloran (PF)

Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada.
Division of Nephrology and Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Georg A Böhmig (GA)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Jonathan Bromberg (J)

Department of Surgery, University of Maryland, Baltimore, MD, United States.

Gunilla Einecke (G)

Department of Nephrology, Hannover Medical School, Hannover, Germany.

Farsad A Eskandary (FA)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Gaurav Gupta (G)

Division of Nephrology, Virginia Commonwealth University, Richmond, VA, United States.

Marek Myslak (M)

Department of Clinical Interventions, Department of Nephrology and Kidney Transplantation Samodzielny Publiczny Wojewódzki Szpital Zespolony (SPWSZ) Hospital, Pomeranian Medical University, Szczecin, Poland.

Ondrej Viklicky (O)

Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.

Agnieszka Perkowska-Ptasinska (A)

Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Katelynn S Madill-Thomsen (KS)

Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada.

Classifications MeSH